Exploration of targeted anti-tumor therapy最新文献

筛选
英文 中文
Targeting the immune microenvironment in blastic plasmacytoid dendritic cell neoplasm: a genomic perspective. 靶向免疫微环境在母细胞浆细胞样树突状细胞肿瘤:一个基因组的观点。
Exploration of targeted anti-tumor therapy Pub Date : 2026-10-27 eCollection Date: 2026-01-01 DOI: 10.37349/etat.2026.1002410
Luigi Cimmino, Martina Lopiano, Valeriia Tsekhovska, Pietro Cimatti, Irma Lapaj, Pier Paolo Piccaluga
{"title":"Targeting the immune microenvironment in blastic plasmacytoid dendritic cell neoplasm: a genomic perspective.","authors":"Luigi Cimmino, Martina Lopiano, Valeriia Tsekhovska, Pietro Cimatti, Irma Lapaj, Pier Paolo Piccaluga","doi":"10.37349/etat.2026.1002410","DOIUrl":"10.37349/etat.2026.1002410","url":null,"abstract":"<p><strong>Background: </strong>Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy originating from precursors of plasmacytoid dendritic cells (pDCs). While normal pDCs are crucial producers of type I interferon (IFN-I) and activators of anti-tumor immunity, BPDCN cells paradoxically lose these functions and create a profoundly immunosuppressive tumor microenvironment (TME).</p><p><strong>Methods: </strong>This systematic review synthesizes recent genomic and molecular insights to detail the intricate connection between the disease's intrinsic landscape and its immune evasion mechanisms, with the goal of informing novel therapeutic strategies.</p><p><strong>Results: </strong>The genomic architecture of BPDCN is marked by frequent cytogenetic abnormalities and pervasive epigenetic dysregulation, defined by recurrent mutations in Tet methylcytosine dioxygenase 2 (<i>TET2</i>) and Additional sex combs like 1 (<i>ASXL1</i>). Furthermore, the survival of malignant cells is sustained by key oncogenic pathways, including the transcription factor 4 (TCF4)-bromodomain-containing protein 4 (BRD4) network and the high expression of the interleukin-3 receptor alpha chain (CD123). Within the TME, these genomic alterations drive T cell exhaustion, suppress natural killer (NK) cell and macrophage function, and promote the expression of immune checkpoints such as programmed death-ligand 1 (PD-L1), while also establishing an immunosuppressive cytokine milieu rich in interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β). The approval of tagraxofusp, the first CD123-targeted therapy, has revolutionized treatment by achieving high response rates and facilitating allogeneic stem cell transplantation (allo-SCT), which remains the only potentially curative option. However, the frequent development of resistance highlights the need for a new paradigm.</p><p><strong>Discussion: </strong>Future directions focus on combination therapies that simultaneously address multiple pathways, such as combining CD123-targeted agents with epigenetic modulators or B-cell lymphoma 2 (BCL2) inhibitors like venetoclax to achieve deeper and more durable responses. This integrated approach is essential for advancing precision medicine and improving outcomes for patients facing this challenging neoplasm.</p>","PeriodicalId":73002,"journal":{"name":"Exploration of targeted anti-tumor therapy","volume":"7 ","pages":"1002410"},"PeriodicalIF":0.0,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13739404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149344922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proteoglycans as regulators of cancer biomarker landscapes: implications for precision oncology. 蛋白聚糖作为癌症生物标志物景观的调节剂:对精确肿瘤学的影响。
Exploration of targeted anti-tumor therapy Pub Date : 2026-10-27 eCollection Date: 2026-01-01 DOI: 10.37349/etat.2026.1002409
Aikaterini Berdiaki, Ioanna Spyridaki, Aristidis Tsatsakis, George Tzanakakis, Dragana Nikitovic
{"title":"Proteoglycans as regulators of cancer biomarker landscapes: implications for precision oncology.","authors":"Aikaterini Berdiaki, Ioanna Spyridaki, Aristidis Tsatsakis, George Tzanakakis, Dragana Nikitovic","doi":"10.37349/etat.2026.1002409","DOIUrl":"10.37349/etat.2026.1002409","url":null,"abstract":"<p><p>In this review, we discuss the dual role of proteoglycans (PGs) in cancer biomarker biology. In addition to serving as biomarkers, PGs regulate the extracellular availability, signaling competence, compartmentalization, and interpretation of numerous disease-associated molecules within the tumor microenvironment. By controlling ligand sequestration, stability, and presentation, PGs influence the biological significance of molecular readouts and signaling-associated signatures. We further examine how extracellular matrix (ECM) remodeling processes, including proteolytic shedding, glycan remodeling, and extracellular vesicle (EV) release, generate circulating molecular signatures that reflect dynamic interactions between tumor cells and their surrounding microenvironment. In parallel, PG-dependent regulation of receptor signaling influences downstream transcriptional and inflammatory response profiles, while regional differences in PG distribution contribute to the formation of distinct ECM niches associated with local variations in signaling activity and molecular expression patterns. Viewed as a whole, these observations indicate that the detectability and clinical interpretation of cancer-associated markers are strongly influenced by PG-dependent extracellular regulation. This framework provides a mechanistic basis for understanding variability in marker performance and supports the incorporation of ECM context into biomarker research. Greater diagnostic precision and improved patient stratification will likely depend on approaches that consider the regulatory roles of PGs within the tumor microenvironment.</p>","PeriodicalId":73002,"journal":{"name":"Exploration of targeted anti-tumor therapy","volume":"7 ","pages":"1002409"},"PeriodicalIF":0.0,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13739403/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149344919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study of the relationship between transposable elements and microRNAs in the development of glioblastoma for its targeted therapy. 转座因子与microrna在胶质母细胞瘤发生及靶向治疗中的关系研究。
Exploration of targeted anti-tumor therapy Pub Date : 2026-10-20 eCollection Date: 2026-01-01 DOI: 10.37349/etat.2026.1002408
Rustam Mustafin
{"title":"Study of the relationship between transposable elements and microRNAs in the development of glioblastoma for its targeted therapy.","authors":"Rustam Mustafin","doi":"10.37349/etat.2026.1002408","DOIUrl":"10.37349/etat.2026.1002408","url":null,"abstract":"<p><p>Glioblastoma (GB) differs from other malignancies in its pronounced aggressiveness, drug resistance (including with modern chemotherapy and anti-PD-1 immunotherapy), high mortality, and the involvement of transposable elements (TEs) in its development. This is reflected in the high frequency of detection of TE-driven chromothripsis in GB samples (39%). Chromothripsis affects chromosomes 7, 9, and 12, with amplification of the <i>EGFR</i> and <i>MDM2/CDK4</i> oncogenes. GB is characterized by the expression of multiple transcripts and peptides derived from specific TEs and stimulating an antitumor immune response. At the same time, LINE1 and a number of long terminal repeat-containing retroelements have been described as having a tumor-promoting effect on GB. Therefore, a differentiated approach to treating GB is promising, with inhibition of TEs involved in carcinogenesis and simultaneous activation of the safest and most immunogenic TEs (viral mimicry). For this approach, it has been proposed to use microRNAs derived from TEs and represented in the MDTE database. A review of the scientific literature identified 43 such microRNAs with tumor suppressor properties. However, additional experimental and clinical studies are needed for their possible use before these molecules can be considered as therapeutic targets. Twenty oncogenic microRNAs derived from TEs were also identified. Interactions of these microRNAs with long noncoding RNAs and circular RNAs in GB pathogenesis are also described.</p>","PeriodicalId":73002,"journal":{"name":"Exploration of targeted anti-tumor therapy","volume":"7 ","pages":"1002408"},"PeriodicalIF":0.0,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13739402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149344921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perioperative immune checkpoint inhibition in head and neck squamous cell carcinoma: a 10-year review. 头颈部鳞状细胞癌围手术期免疫检查点抑制:10年回顾
Exploration of targeted anti-tumor therapy Pub Date : 2026-10-19 eCollection Date: 2026-01-01 DOI: 10.37349/etat.2026.1002406
Henry Freeman, Clayton Rawson, Nadir Al-Saidi, Brandon Lucke-Wold, Michael Karsy, Mehrdad Pahlevani
{"title":"Perioperative immune checkpoint inhibition in head and neck squamous cell carcinoma: a 10-year review.","authors":"Henry Freeman, Clayton Rawson, Nadir Al-Saidi, Brandon Lucke-Wold, Michael Karsy, Mehrdad Pahlevani","doi":"10.37349/etat.2026.1002406","DOIUrl":"10.37349/etat.2026.1002406","url":null,"abstract":"<p><p>Immune checkpoint blockade has transformed management of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), yet efforts to integrate immunotherapy into curative chemoradiation have failed to improve outcomes. We conducted a narrative review of English-language literature published between 2015 and 2025, searching PubMed/MEDLINE, Embase, Web of Science, and ClinicalTrials.gov for perioperative (neoadjuvant and/or adjuvant) immunotherapy studies in resectable HNSCC, and reviewed translational and cross-tumor neoadjuvant data relevant to perioperative trial design. Across early-phase and randomized perioperative trials, neoadjuvant programmed cell death 1 (PD-1)-based strategies were consistently feasible and induced pathologic tumor regression in a subset of patients. Protocol-defined, treatment-related surgical delays were uncommon; however, delays overall were more frequent with perioperative pembrolizumab in the phase III setting (38 vs. 10 participants in KEYNOTE-689; median time to surgery 3.0 vs. 1.9 weeks), so preserved surgical deliverability should not be equated with absence of scheduling impact. Phase II studies associated depth of pathologic response and immune-inflamed tumor features with improved disease-free outcomes. These findings informed phase III perioperative trials, culminating in KEYNOTE-689, which improved event-free survival without compromising surgical completion. In contrast, phase III trials evaluating concurrent PD-1/programmed death-ligand 1 (PD-L1) checkpoint blockade with definitive chemoradiotherapy showed no meaningful survival benefit. Collectively, current evidence supports perioperative pembrolizumab added to surgery and risk-adapted adjuvant therapy in selected patients with resectable locally advanced HNSCC, while other perioperative immune checkpoint inhibitor regimens remain investigational. This conclusion rests principally on a single positive phase III trial (KEYNOTE-689), and the June 2025 FDA approval is restricted to tumors with a PD-L1 combined positive score (CPS) of at least 1. The relative contributions of neoadjuvant priming, concurrent postoperative therapy, and prolonged adjuvant maintenance cannot be disentangled within the KEYNOTE-689 design, and no perioperative schedule can yet be designated optimal. Ongoing studies will refine biomarker-guided selection, sequencing, and duration.</p>","PeriodicalId":73002,"journal":{"name":"Exploration of targeted anti-tumor therapy","volume":"7 ","pages":"1002406"},"PeriodicalIF":0.0,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13739399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149344918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liquid biopsy in genitourinary cancers: circulating tumor DNA as a predictive biomarker for treatment selection and resistance monitoring. 泌尿生殖系统癌的液体活检:循环肿瘤DNA作为治疗选择和耐药性监测的预测性生物标志物。
Exploration of targeted anti-tumor therapy Pub Date : 2026-10-19 eCollection Date: 2026-01-01 DOI: 10.37349/etat.2026.1002407
Alcides Chaux, Andrea Paola Britos Gómez
{"title":"Liquid biopsy in genitourinary cancers: circulating tumor DNA as a predictive biomarker for treatment selection and resistance monitoring.","authors":"Alcides Chaux, Andrea Paola Britos Gómez","doi":"10.37349/etat.2026.1002407","DOIUrl":"10.37349/etat.2026.1002407","url":null,"abstract":"<p><strong>Background: </strong>Genitourinary (GU) cancers-prostate, urothelial, and renal cell carcinomas (RCCs)-are a leading source of oncologic morbidity and mortality. Tumor heterogeneity and evolving resistance limit static tissue biopsies, requiring real-time, non-invasive biomarkers. Circulating tumor DNA (ctDNA) captures the tumor's mutational landscape in real time and has emerged as a candidate biomarker for treatment selection and resistance monitoring in GU malignancies.</p><p><strong>Methods: </strong>An integrative review was conducted by two independent reviewers following the Whittemore and Knafl integrative review framework, informed by PRISMA 2020 conventions. Searches covered PubMed/MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and Web of Science (January 2020-April 2026). Screening and extraction were performed independently by both reviewers, with disagreements resolved by consensus. After deduplication, 118 records were screened, 39 assessed in full text, and 15 studies met inclusion criteria, stratified by cancer site.</p><p><strong>Results: </strong>ctDNA functions primarily as a prognostic and treatment-monitoring biomarker across GU malignancies, with predictive utility for treatment selection well established in muscle-invasive bladder cancer (MIBC) and still maturing elsewhere. In castration-resistant prostate cancer (CRPC), ctDNA tumor fraction (TF) at enzalutamide cycle 3 independently predicts progression-free and overall survival (OS; median OS 16.0 vs. 22.1 months, ctDNA-detected vs. -undetected with discordant prostate-specific antigen). In MIBC, post-cystectomy ctDNA identifies relapse with 94% sensitivity and 98% specificity, and a ctDNA-stratified IMvigor010 analysis reveals an OS benefit from adjuvant atezolizumab [hazard ratio (HR) 0.59] in ctDNA-positive patients only. In RCC, the least mature stratum, cfDNA quantity, <i>TP53</i> mutation, TF, and <i>BAP1</i> status are associated with survival on systemic therapy. In upper tract urothelial carcinoma (UTUC), perioperative ctDNA fraction predicts recurrence-free survival, with clonal haematopoiesis accounting for a notable share of false positives.</p><p><strong>Conclusion: </strong>ctDNA is a molecularly grounded biomarker with the strongest evidence in metastatic CRPC (mCRPC) and MIBC, an expanding but preliminary base in RCC, and limited capacity, outside MIBC, to guide treatment selection.</p>","PeriodicalId":73002,"journal":{"name":"Exploration of targeted anti-tumor therapy","volume":"7 ","pages":"1002407"},"PeriodicalIF":0.0,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13739405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149344861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Wound healing and recurrence in head and neck cancer: a narrative review. 头颈癌的伤口愈合和复发:一个叙述性的回顾。
Exploration of targeted anti-tumor therapy Pub Date : 2026-10-15 eCollection Date: 2026-01-01 DOI: 10.37349/etat.2026.1002405
Micah K Harris, Wesley L Cai, Jenny Kim, Vanessa Helou, Joshua D Smith, Matthew E Spector
{"title":"Wound healing and recurrence in head and neck cancer: a narrative review.","authors":"Micah K Harris, Wesley L Cai, Jenny Kim, Vanessa Helou, Joshua D Smith, Matthew E Spector","doi":"10.37349/etat.2026.1002405","DOIUrl":"10.37349/etat.2026.1002405","url":null,"abstract":"<p><p>There is a growing body of evidence showing that the postoperative wound healing response shares molecular machinery with tumor pathways. Within larger surgical fields such as breast or colorectal cancer, strong preclinical and clinical evidence exists demonstrating a link between postoperative wound complications and cancer recurrence. Head and neck surgery represents a unique landscape with high rates of surgical site infections (SSIs; 20-30%), driven in part by inherent wound contamination from the aerodigestive tract, in addition to prolonged operative times, malnutrition, smoking, and poor overall health. Despite this, studies addressing postoperative wound healing and head and neck cancer (HNC) recurrence remain fragmented at best, with studies demonstrating significant heterogeneity and conflicting results. A thorough understanding of the oncologic implications of wound complications in HNC is vitally important to improve patient outcomes and identify novel therapeutic strategies. This narrative review seeks to synthesize preclinical and clinical studies linking the postoperative wound environment to HNC recurrence. We also seek to highlight emerging approaches to optimize postoperative wound healing for an oncologic benefit, including the role of surgical drain fluid as a novel bioresource, alternative reconstructive hardware, the role of neoadjuvant immunotherapy, and emerging biomaterials.</p>","PeriodicalId":73002,"journal":{"name":"Exploration of targeted anti-tumor therapy","volume":"7 ","pages":"1002405"},"PeriodicalIF":0.0,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13739400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149344923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Redefining axillary management by selecting patients for omission of sentinel lymph node surgery in early breast cancer. 通过选择早期乳腺癌遗漏前哨淋巴结手术的患者重新定义腋窝治疗。
Exploration of targeted anti-tumor therapy Pub Date : 2026-10-09 eCollection Date: 2026-01-01 DOI: 10.37349/etat.2026.1002404
Wiebren Tjalma, Seppe Coenen
{"title":"Redefining axillary management by selecting patients for omission of sentinel lymph node surgery in early breast cancer.","authors":"Wiebren Tjalma, Seppe Coenen","doi":"10.37349/etat.2026.1002404","DOIUrl":"10.37349/etat.2026.1002404","url":null,"abstract":"<p><p>Axillary staging has traditionally been performed routinely in early breast cancer to provide prognostic information and guide adjuvant therapy. In the era of targeted anti-tumor therapy and biology-driven treatment selection, however, the therapeutic relevance of nodal status has diminished in selected patients with clinically node-negative disease. Recent randomized trials, including Sentinel node vs. Observation after axillary UltraSouND (SOUND), INtergroup SEntinel MAmma trial (INSEMA), and Dutch Breast Cancer Research Group (BOrstkanker Onderzoek Groep; BOOG) 2013-08, have demonstrated that omission of sentinel lymph node biopsy (SLNB) in carefully selected patients undergoing breast-conserving surgery with planned whole-breast radiotherapy (WBRT) does not compromise local or distant disease control and rarely alters adjuvant systemic or radiotherapy management. The most robust evidence applies to postmenopausal women aged ≥ 50 years with ductal tumors ≤ 2 cm, grade 1-2, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative and clinically node-negative disease. In this biologically favorable population, the therapeutic impact of nodal findings is limited as systemic therapy and radiotherapy decisions are predominantly driven by tumor subtype and genomic risk stratification rather than minimal nodal involvement. Based on evidence from recent randomized trials and current guidelines, this position paper proposes a practical four-step framework for decision-making regarding omission of SLNB. Redefining the axilla in this context represents a precision-oncology approach to surgical de-escalation, aligning local treatment intensity with biological risk while preserving oncologic safety.</p>","PeriodicalId":73002,"journal":{"name":"Exploration of targeted anti-tumor therapy","volume":"7 ","pages":"1002404"},"PeriodicalIF":0.0,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13739401/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149344920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addition of immune checkpoint inhibitor to standard of care chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis. 局部晚期鼻咽癌患者在标准护理放化疗中加入免疫检查点抑制剂:一项系统回顾和荟萃分析
Exploration of targeted anti-tumor therapy Pub Date : 2026-09-28 eCollection Date: 2026-01-01 DOI: 10.37349/etat.2026.1002403
Ramaditya Srinivasmurthy, Jason Ta, Sharif Afifi, Taimur Khalid, Hazem Aboaid, Rishi Kumar Nanda, Daniel Thomas Jones, Kenny Do, Kevin Nguyen, Karina Fama, Sarah Aamer, Yin Mon Myat, Jo-Lawrence Bigcas, Kyaw Zin Thein
{"title":"Addition of immune checkpoint inhibitor to standard of care chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis.","authors":"Ramaditya Srinivasmurthy, Jason Ta, Sharif Afifi, Taimur Khalid, Hazem Aboaid, Rishi Kumar Nanda, Daniel Thomas Jones, Kenny Do, Kevin Nguyen, Karina Fama, Sarah Aamer, Yin Mon Myat, Jo-Lawrence Bigcas, Kyaw Zin Thein","doi":"10.37349/etat.2026.1002403","DOIUrl":"https://doi.org/10.37349/etat.2026.1002403","url":null,"abstract":"<p><strong>Background: </strong>Preliminary findings from this study were previously published as a conference abstract (https://doi.org/10.1158/2326-6074.IO2025-B039). Immune checkpoint inhibitors (ICIs) have shown activity in nasopharyngeal carcinoma (NPC), but their efficacy and safety when integrated with standard chemoradiotherapy (CRT) for locally advanced NPC remain under investigation. We performed a systematic review and meta-analysis of randomized controlled trials evaluating the efficacy and safety of integrating ICIs with standard CRT-based treatment in patients with locally advanced NPC.</p><p><strong>Methods: </strong>MEDLINE and EMBASE were searched from inception through September 1, 2025, for English-language phase II or III randomized controlled trials evaluating ICIs plus standard therapy. Eligible studies reported efficacy outcomes, including progression-free/event-free survival (PFS/EFS), overall survival (OS), distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRFS), and/or safety outcomes. Hazard ratios (HRs) were pooled using the generic inverse variance method, and risk ratios (RRs) for adverse events were pooled using the Mantel-Haenszel method. Fixed-effect models were used, with heterogeneity assessed using <i>I</i> <sup>2</sup> statistics.</p><p><strong>Results: </strong>Three trials randomized 1,022 patients: CONTINUUM (<i>n</i> = 423), DIPPER (<i>n</i> = 450), and a phase II toripalimab trial (<i>n</i> = 149). The pooled safety population included 998 patients. ICIs significantly improved PFS/EFS [HR 0.54; 95% confidence interval (CI): 0.40-0.72; <i>P</i> < 0.0001], DMFS (HR 0.52; 95% CI: 0.36-0.75; <i>P</i> = 0.0005), and LRFS (HR 0.47; 95% CI: 0.31-0.71; <i>P</i> = 0.0003). OS favored the ICI arm but was not statistically significant (HR 0.77; 95% CI: 0.49-1.20; <i>P</i> = 0.24). ICIs increased immune related adverse events, whereas most CRT-associated locoregional and hematologic toxicities were not significantly increased.</p><p><strong>Discussion: </strong>Adding ICIs to standard CRT based therapy significantly improved disease control outcomes, including PFS/EFS, DMFS, and LRFS, without broadly worsening the overall CRT associated toxicity profile. Longer follow up is needed to determine whether these early disease control benefits translate into a statistically significant OS advantage.</p>","PeriodicalId":73002,"journal":{"name":"Exploration of targeted anti-tumor therapy","volume":"7 ","pages":"1002403"},"PeriodicalIF":0.0,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13623625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149119138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Significance of next-generation sequencing in the era of targeted therapy for biliary tract cancer: an analysis at a single institution. 下一代测序在胆道癌靶向治疗时代的意义:单个机构的分析。
Exploration of targeted anti-tumor therapy Pub Date : 2026-09-18 eCollection Date: 2026-01-01 DOI: 10.37349/etat.2026.1002402
Kei Nakagawa, Hideaki Sato, Masahiro Iseki, Daisuke Douchi, Shuichi Aoki, Michiaki Unno
{"title":"Significance of next-generation sequencing in the era of targeted therapy for biliary tract cancer: an analysis at a single institution.","authors":"Kei Nakagawa, Hideaki Sato, Masahiro Iseki, Daisuke Douchi, Shuichi Aoki, Michiaki Unno","doi":"10.37349/etat.2026.1002402","DOIUrl":"10.37349/etat.2026.1002402","url":null,"abstract":"<p><strong>Aim: </strong>Treatment approaches for biliary tract cancer (BTC) vary widely. Genomic profiling through next-generation sequencing (NGS) has made it possible to apply precision medicine in the management of BTC. This retrospective observational study aimed to evaluate the implementation of treatments based on identified genomic mutations and their clinical significance in patients with BTC in Japan, where NGS is covered by health insurance.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 65 patients with unresectable or recurrent BTC who underwent comprehensive genomic profiling at a single institution between November 2019 and October 2024. Genomic mutations were classified according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) scale. Overall survival (OS) was estimated using the Kaplan-Meier method and compared using the log-rank test.</p><p><strong>Results: </strong>Among the 65 patients, clinically relevant genomic mutations classified using the ESCAT scale were identified in 47 patients, and clinically treatable genomic mutations were identified in 13 patients. Six patients ultimately received mutation-guided therapy, including fibroblast growth factor receptor inhibitors and pembrolizumab. The median time from specimen submission to review by the expert panel was 26 (range, 16-40) days. No significant difference in OS was observed based on the site of the primary tumor (log-rank test, <i>P</i> = 0.5804).</p><p><strong>Conclusions: </strong>Although clinically actionable genomic mutations were identified in one-fifth of patients, < 10% ultimately received treatment based on those findings, highlighting a gap between genomic profiling and treatment implementation. In contrast, with the increasing number of available therapies, access to precision treatment for patients with BTC may improve in the future through a combination of early adoption of NGS and the complementary use of liquid biopsy when tissue is unavailable.</p>","PeriodicalId":73002,"journal":{"name":"Exploration of targeted anti-tumor therapy","volume":"7 ","pages":"1002402"},"PeriodicalIF":0.0,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13586963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149009439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiotoxicity in breast cancer patients treated with chemoradiotherapy. 乳腺癌放化疗患者的心脏毒性。
Exploration of targeted anti-tumor therapy Pub Date : 2026-09-14 eCollection Date: 2026-01-01 DOI: 10.37349/etat.2026.1002401
Peter Emerson, Liza Thomas
{"title":"Cardiotoxicity in breast cancer patients treated with chemoradiotherapy.","authors":"Peter Emerson, Liza Thomas","doi":"10.37349/etat.2026.1002401","DOIUrl":"10.37349/etat.2026.1002401","url":null,"abstract":"<p><p>With national breast cancer screening programs leading to earlier diagnosis and improved treatments, more women are achieving long-term remission. However, this has resulted in rising rates of cardiotoxicity in breast cancer survivors consequent to their cancer therapies. Anthracyclines, a cornerstone treatment in breast cancer, carry a significant risk of short- and long-term cardiotoxicity through inhibition of topoisomerase II, preventing DNA repair and increasing oxidative stress. This most commonly manifests in the form of left ventricular (LV) systolic dysfunction or heart failure, and in severe cases, death. Many of the other treatments, including taxanes, cyclophosphamide, human epidermal growth factor receptor 2 inhibitors, immunotherapies, hormone therapies, and radiotherapy, also carry a risk of cardiac injury in the form of heart failure, arrhythmias, myocarditis, and pericardial disease. Surveillance has traditionally been performed by monitoring LV ejection fraction by transthoracic echocardiography. However, this has been found to be a late marker of cardiotoxicity, with damage potentially irreversible, and may reflect a missed opportunity for early intervention. Research has focused on identifying cardiac biomarkers and advanced imaging techniques, including strain analysis, to detect subclinical myocardial injury or dysfunction prior to irreversible damage, with LV global longitudinal strain a sensitive marker of subclinical LV systolic dysfunction and superior predictor of future cardiovascular events. Further research is needed to establish standardized guidelines on surveillance and management of this vulnerable patient cohort.</p>","PeriodicalId":73002,"journal":{"name":"Exploration of targeted anti-tumor therapy","volume":"7 ","pages":"1002401"},"PeriodicalIF":0.0,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13586964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149009495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书